Sanofi SA

Sanofi’s $2.2 billion Dynavax deal boosts its vaccine pipeline, yet a tolebrutinib CRL and new Wayrilz approval highlight both regulatory risks and growth opportunities.

Sanofi’s $2.2 B Dynavax buy, EU Wayrilz approval and FDA response to tolebrutinib reveal a bold strategy to diversify vaccines, autoimmune and neuro‑degenerative therapies while navigating tougher regulatory hurdles.

Sanofi’s $2.2 billion Dynavax deal boosts its U.S. vaccine lineup, adding hepatitis‑B and shingles candidates, while an FDA CRL on tolebrutinib shows regulatory hurdles for its MS therapy.

Sanofi’s $1.7 billion partnership with Dren Bio offers a high‑potential biologics boost, while a failed PPMS trial tests its MS pipeline and investor confidence.

Sanofi partners with Dren Bio for up to $1.7 billion to expand antibody‑based autoimmune therapies, while its tolebrutinib MS trial falls short, reshaping its pipeline and investor outlook.

Sanofi’s December 2025 NMPA approvals for Qfitlia and Cablivi, plus the ViceBio ADC acquisition, position the company to dominate China’s rare‑disease market, yet reimbursement shifts and integration risks could impact long‑term gains.

Sanofi’s new EU approval for Dupixent in chronic spontaneous urticaria could unlock €200 million of revenue, but a growing French tax probe may dent the stock.

Texas AG sues Sanofi and Bristol‑Myers over Plavix data gaps, exposing how undisclosed subgroup results may mislead doctors and patients about heart‑attack risk.

Sanofi’s third-quarter earnings report exceeded expectations, driven by strong sales of its flagship product Dupixent, which surpassed €4 billion in revenue for the first time, and the company reaffirmed its 2025 outlook while signaling optimism f…

Sanofi’s Wayrilz, a groundbreaking BTK inhibitor, has received US approval for the treatment of immune thrombocytopenia, a condition characterized by low platelet count.